Tagged ards

VidaTalk Translates Better Care
Press Release

VidaTalk Translates Better Care

 VidaTalk announces new feature enabling health care providers to communicate with non-English speaking patients during routine care interactions without an interpreter. Read More
Study Shows VidaTalk Reduces Psychological Stress and Improves Neuromotor Coordination During Critical Illness
Press Release

Study Shows VidaTalk Reduces Psychological Stress and Improves Neuromotor Coordination During Critical Illness

 Moving away from yes/no questions and simple requests to meaningful dialogue amongst critically ill speechless patients, their families and care providers Read More
VidaTalk Translates Better Care
Press Release

VidaTalk Translates Better Care

 VidaTalk announces new feature enabling health care providers to communicate with non-English speaking patients during routine care interactions without an interpreter. Read More
VidaTalk Provides a Voice to COVID-19 Patients
Press Release

VidaTalk Provides a Voice to COVID-19 Patients

 Vidatak extends its offer of unlimited downloads of its VidaTalk application to Michigan-based healthcare providers to aid critical doctor-patient communications during the pandemic. Read More
Direct Biologics Granted Expanded Access by FDA for ExoFlo™ in the Treatment of COVID-19
Press Release

Direct Biologics Granted Expanded Access by FDA for ExoFlo™ in the Treatment of COVID-19

 Read More
Press Release

Direct Biologics Initiates Patient Enrollment in the Phase II EXIT COVID-19 Clinical Trial

 Phase II Clinical Trial Initiated for ExoFlo Extracellular Vesicles in the Treatment of COVID-19 Read More
Press Release

GB Sciences Files Provisional Patent Application for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome (ARDS), the Leading Cause of Hospitalization and Deaths, Utilizing Its Cannabinoid Containing Complex Mixtures (CCCM™)

 Based on data from a two-year study, GBS's CCCM were designed for the treatment of Cytokine Storm Syndromes, while preserving anti-viral immune reactions Read More
Longeveron Announces Japanese Approval of Clinical Trial for Treatment of Aging Frailty With Longeveron's Stem Cells
Press Release

Longeveron Announces Japanese Approval of Clinical Trial for Treatment of Aging Frailty With Longeveron's Stem Cells

 The Phase 2 study will assess the safety and efficacy of Longeveron's stem cell treatment under Japan's accelerated regulatory pathway for regenerative medicine. Read More
Press Release

Two Research Reports Cite HemogloBind™ for Highly Efficient Sample Preparation

 Read More